Efficacy and Safety of Avandamet or Uptitrated Metformin Treatment in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Controlled Trial
文献类型：期刊论文
| 作者 | Cai XiaoLing7; Chen YingLi7; Zhao JiaJun6; Shan ZhongYan5; Qiu MingCai4; Li ChengJiang3; Gu Wei3; Tian HaoMing8; Yang HuaZhang2; Xue YaoMing2 |
| 刊名 | Chinese Medical Journal
 |
| 出版日期 | 2015 |
| 卷号 | 128期号:10页码:1279-1287 |
| ISSN号 | 0366-6999 |
| 关键词 | Avandamet Medicine R Efficacy Type 2 Diabetes |
| 其他题名 | Efficacy and Safety of Avandamet or Uptitrated Metformin Treatment in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Controlled Trial |
| 英文摘要 | Background: At present, China has listed the compound tablet containing a fixed dose of rosiglitazone and metformin, Avandamet, which may improve patient compliance. The aim of this study was to evaluate the efficacy and safety of Avandamet or uptitrated metformin treatment in patients with type 2 diabetes inadequately controlled with metformin alone. Methods: This study was a 48-week, multicenter, randomized, open-labeled, active-controlled trial. Patients with inadequate glycaemic control (glycated hemoglobin HbA1c 7.5-9.5%) receiving a stable dose of metformin (≥1500 mg) were recruited from 21 centers in China (from 19 November, 2009 to 15 March, 2011). The primary objective was to compare the proportion of patients who reached the target of HbA1c ≤7% between Avandamet and metformin treatment. Results: At week 48, 83.33% of patients reached the target of HbA1c ≤7% in Avandamet treatment and 70.00% in uptitrated metformin treatment, with significantly difference between groups. The target of HbA1c ≤6.5% was reached in 66.03% of patients in Avandamet treatment and 46.88% in uptitrated metformin treatment. The target of fasting plasma glucose (FPG) ≤6.1 mmol/L was reached in 26.97% of patients in Avandamet treatment and 19.33% in uptitrated metformin treatment. The target of FPG ≤7.0 mmol/L was reached in 63.16% of patients in Avandamet treatment and 43.33% in uptitrated metformin treatment. Fasting insulin decreased 3.24 ± 0.98 μU/ml from baseline in Avandamet treatment and 0.72 ± 1.10 μU/ml in uptitrated metformin treatment. Overall adverse event (AE) rates and serious AE rates were similar between groups. Hypoglycaemia occurred rarely in both groups. Conclusions: Compared with uptitrated metformin, Avandamet treatment provided significant improvements in key parameters of glycemic control and was generally well tolerated. Registration number: ChiCTR-TRC-13003776. |
| 资助项目 | [GlaxoSmithKline] |
| 语种 | 英语 |
| CSCD记录号 | CSCD:5419638 |
| 源URL | [http://ir.imr.ac.cn/handle/321006/153602]  |
| 专题 | 金属研究所_中国科学院金属研究所 |
| 作者单位 | 1.Beijing Tongren Hosp, Department Endocrinol & Metab, Beijing 100730, Peoples R China 2.中国科学院广州地球化学研究所 3.浙江大学 4.Tianjin Med University, Gen Hosp, Dept Endocrinol & Metab, Tianjin 300070, Peoples R China 5.中国科学院金属研究所 6.Shandong Prov Hosp, Department Endocrinol & Metab, Jinan 250021, Shandong, Peoples R China 7.北京大学 8.四川大学 |
| 推荐引用方式 GB/T 7714 | Cai XiaoLing,Chen YingLi,Zhao JiaJun,et al. Efficacy and Safety of Avandamet or Uptitrated Metformin Treatment in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Controlled Trial[J]. Chinese Medical Journal,2015,128(10):1279-1287. |
| APA | Cai XiaoLing.,Chen YingLi.,Zhao JiaJun.,Shan ZhongYan.,Qiu MingCai.,...&Ji LiNong.(2015).Efficacy and Safety of Avandamet or Uptitrated Metformin Treatment in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Controlled Trial.Chinese Medical Journal,128(10),1279-1287. |
| MLA | Cai XiaoLing,et al."Efficacy and Safety of Avandamet or Uptitrated Metformin Treatment in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Controlled Trial".Chinese Medical Journal 128.10(2015):1279-1287. |
入库方式： OAI收割
来源：金属研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。